71 related articles for article (PubMed ID: 20869878)
1. Bryostatin-I: a dendritic cell stimulator for chemokines induction and a promising adjuvant for a peptide based cancer vaccine.
Yan W; Chen WC; Liu Z; Huang L
Cytokine; 2010 Dec; 52(3):238-44. PubMed ID: 20869878
[TBL] [Abstract][Full Text] [Related]
2. Bryostatin-1 enhances the maturation and antigen-presenting ability of murine and human dendritic cells.
Do Y; Hegde VL; Nagarkatti PS; Nagarkatti M
Cancer Res; 2004 Sep; 64(18):6756-65. PubMed ID: 15374994
[TBL] [Abstract][Full Text] [Related]
3. Precursor frequency analysis of bryostatin activated lymphocytes.
Fleming MD; Barrett SK; Bear HD
J Surg Res; 1994 Jul; 57(1):74-9. PubMed ID: 8041153
[TBL] [Abstract][Full Text] [Related]
4. [Dendritic cells present particulate E7 protein of human papillomavirus and induce strong immunity].
Li J; Gao HQ; Zhao CL; Li LZ; Ji CY; Hou M; Plebaski M
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):932-6. PubMed ID: 15329282
[TBL] [Abstract][Full Text] [Related]
5. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
6. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
[TBL] [Abstract][Full Text] [Related]
7. Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine.
Yan W; Chen W; Huang L
J Control Release; 2008 Aug; 130(1):22-8. PubMed ID: 18554742
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines.
Yan W; Chen W; Huang L
Mol Immunol; 2007 Jul; 44(15):3672-81. PubMed ID: 17521728
[TBL] [Abstract][Full Text] [Related]
10. Bryostatin-1, a naturally occurring antineoplastic agent, acts as a Toll-like receptor 4 (TLR-4) ligand and induces unique cytokines and chemokines in dendritic cells.
Ariza ME; Ramakrishnan R; Singh NP; Chauhan A; Nagarkatti PS; Nagarkatti M
J Biol Chem; 2011 Jan; 286(1):24-34. PubMed ID: 21036898
[TBL] [Abstract][Full Text] [Related]
11. Bryostatin-1 and IFN-gamma synergize for the expression of the inducible nitric oxide synthase gene and for nitric oxide production in murine macrophages.
Taylor LS; Cox GW; Melillo G; Bosco MC; Espinoza-Delgado I
Cancer Res; 1997 Jun; 57(12):2468-73. PubMed ID: 9192827
[TBL] [Abstract][Full Text] [Related]
12. Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7.
Dell K; Klein C; Gissmann L
Antivir Ther; 2008; 13(4):495-509. PubMed ID: 18672528
[TBL] [Abstract][Full Text] [Related]
13. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion.
Daftarian P; Mansour M; Benoit AC; Pohajdak B; Hoskin DW; Brown RG; Kast WM
Vaccine; 2006 Jun; 24(24):5235-44. PubMed ID: 16675074
[TBL] [Abstract][Full Text] [Related]
14. Response of Jurkat T cells to phorbol ester and bryostatin. Development of sublines with distinct functional responses and changes in protein kinase C activity.
Levine BL; May WS; Tyler PG; Hess AD
J Immunol; 1991 Nov; 147(10):3474-81. PubMed ID: 1834742
[TBL] [Abstract][Full Text] [Related]
15. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo.
Tüting T; DeLeo AB; Lotze MT; Storkus WJ
Eur J Immunol; 1997 Oct; 27(10):2702-7. PubMed ID: 9368629
[TBL] [Abstract][Full Text] [Related]
16. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity.
Saha A; Chatterjee SK; Foon KA; Primus FJ; Bhattacharya-Chatterjee M
Cancer Res; 2003 Jun; 63(11):2844-54. PubMed ID: 12782590
[TBL] [Abstract][Full Text] [Related]
17. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
[TBL] [Abstract][Full Text] [Related]
18. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
Tuttle TM; Inge TH; Bethke KP; McCrady CW; Pettit GR; Bear HD
Cancer Res; 1992 Feb; 52(3):548-53. PubMed ID: 1732041
[TBL] [Abstract][Full Text] [Related]
19. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
20. Bryostatin 1 acts synergistically with interleukin-1 alpha to induce secretion of G-CSF and other cytokines from marrow stromal cells.
Lilly M; Vo K; Le T; Takahashi G
Exp Hematol; 1996 Apr; 24(5):613-21. PubMed ID: 8605966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
